RIPK1 and myeloid sarcoma: We used the sensitivity of the Meso Scale Discovery (MSD) platform to assess RIPK1 activation and expression levels, demonstrating increased pRIPK1 and total RIPK1 levels in progressive MS compared with RRMS and NAWM controls (Figures S1C and S1D).